cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) (PDE4)

cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) is a major enzyme family responsible for the hydrolysis and inactivation of the second messenger cyclic adenosine monophosphate (cAMP) within immune and inflammatory cells [1]. By regulating the local concentration of cAMP, PDE4 plays a central role in modulating signal transduction pathways that control the expression of inflammatory mediators and the activation of leukocytes [2]. There are four isoforms (PDE4A, B, C, and D), with PDE4B and PDE4D being the most prominent targets for anti-inflammatory therapy [3]. Dysregulation of the PDE4 pathway is linked to the pathogenesis of various chronic inflammatory conditions, including COPD, psoriasis, and asthma [4]. Pharmacological inhibition of PDE4 leads to elevated cAMP levels, which suppresses the production of pro-inflammatory cytokines such as TNF-alpha and interferon-gamma while increasing anti-inflammatory signals [5]. Although effective, clinical use of PDE4 inhibitors is frequently limited by systemic side effects, particularly nausea and emesis, which are thought to be mediated by the inhibition of the PDE4D isoform in the central nervous system [6].

Other names

Phosphodiesterase 4PDE4 familycAMP-specific phosphodiesteraseCyclic AMP-specific phosphodiesterase

Inhibition of PDE4 prevents the hydrolysis of cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP levels. This elevation activates protein kinase A (PKA) and other downstream effectors, resulting in the suppression of pro-inflammatory cytokine production (e.g., TNF-alpha, IL-17, IL-23) and the promotion of anti-inflammatory mediators.